Stock Market Reviews

Read and share opinions on MRK (Merck & Co., Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential
  Dec 30, 2025
• Where is Merck & Co. (MRK) Headed According to Wall Street?
  Dec 30, 2025
• Why Merck (MRK) Outpaced the Stock Market Today
  Dec 24, 2025
• Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
  Dec 23, 2025
• “Merck (MRK) is an Inexpensive Stock,” Says Jim Cramer
  Dec 22, 2025

MRK News

• Where is Merck & Co. (MRK) Headed According to Wall Street?
  Merck & Co., Inc. (NYSE:MRK) is one of the best affordable healthcare stocks to buy now. Jefferies analyst Tycho Peterson reaffirmed a Buy rating on Merck & Co., Inc. (NYSE:MRK) on December 19 and set a $139.00 price target. The same day, Merck & Co., Inc. (NYSE:MRK) announced a historic agreement with the Trump administration to […]
  Dec 30, 2025
• 3 Drug Stocks to Buy at a Discount
  The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.
  Dec 27, 2025
• Can J&J's Pipeline Progress in 2025 Aid Long-Term Growth?
  JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.
  Dec 26, 2025
• Why Merck (MRK) Outpaced the Stock Market Today
  The latest trading day saw Merck (MRK) settling at $106.45, representing a +1.34% change from its previous close.
  Dec 24, 2025
• Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know
  AMGN signs a pricing deal with the Trump administration, cutting U.S. drug costs, expanding DTC access and securing tariff relief tied to domestic investment.
  Dec 24, 2025
• PFE's Oncology & Obesity Pipeline Position It for Post-LOE Growth
  Pfizer faces revenue pressure from 2026-2030 LOEs but is betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth.
  Dec 24, 2025
• Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
  Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
  Dec 23, 2025
• Will the Recent Pricing Deal With the Government Impact BMY's Sales?
  BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.
  Dec 23, 2025
• Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
  Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
  Dec 22, 2025
• “Merck (MRK) is an Inexpensive Stock,” Says Jim Cramer
  We recently published 8 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radars. Pharma giant Merck & Co., Inc. (NYSE:MRK)’s shares are up by 1.9% year-to-date on the back of a strong run since early November. Before the run started, the stock was down 16.8% […]
  Dec 22, 2025
• This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.
  Vaxcyte stock kept its place as one of Mizuho’s top picks entering 2026, with the firm reiterating an Outperform rating and a $163 price target in a research note. Vaxcyte is advancing to phase 3 trials for its shot, VAX-31, in adults and phase 2 trials for infants. It could eventually be a leader in an $8 billion market, Mizuho argued.
  Dec 22, 2025
• Radiopharmaceutical specialist Aktis seeks an IPO
  The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.
  Dec 22, 2025
• Jim Cramer Discusses Kura Oncology as a Speculative Bet
  Kura Oncology, Inc. (NASDAQ:KURA) is one of the stocks Jim Cramer offered insights on. When a caller highlighted the company’s $135 million milestone payment owing to its U.S. commercial sale of KOMZIFTI, Cramer commented: “That’s a lot. That is a lot… Now, just understand that, yeah, they are milestone payments, not actual. Now, here’s what […]
  Dec 21, 2025
• Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs
  We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]
  Dec 19, 2025
• Merck (MRK)’s CEO Has a “Better Hand,” Says Jim Cramer
  We recently published 12 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radar. Merck & Co., Inc. (NYSE:MRK) is one of the largest pharmaceutical companies in the world. Its shares are flat year-to-date and would have been lower had it not been for a run […]
  Dec 19, 2025
• Here's Why Merck (MRK) is a Strong Growth Stock
  The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
  Dec 19, 2025
• Trump reaches deal with 9 drug companies to lower prices
  President Trump announced deals with nine major drug makers in a move to reduce pharmaceutical prices, granting a three-year break on trade tariffs if they invest more into US manufacturing. Market Domination Overtime host Jared Blikre breaks down the news. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.
  Dec 19, 2025
• Pharma's $370B Bet on America: The ETF Plays for 2026
  Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.
  Dec 19, 2025
• Sector Update: Health Care Stocks Rise Late Afternoon
  Health care stocks rose late Friday afternoon, with the NYSE Health Care Index increasing 0.8% and t
  Dec 19, 2025
• Better Buy in 2026: Pfizer or Merck?
  This year has been one to forget for these pharmaceutical giants.
  Dec 19, 2025
• Top Midday Stories: Oracle, Others Form JV to Oversee TikTok in US; More Drugmakers to Announce US Drug Price Deals
  All three major US stock indexes were up in late-morning trading Friday, as the artificial-intellige
  Dec 19, 2025
• Nine Drugmakers Strike Deals With Trump, With More to Come
  The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.
  Dec 19, 2025
• Jim Cramer Explains How Market Rotation Boosted Companies Like Johnson & Johnson
  Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer talked about recently. Cramer mentioned the stock during the episode and said: “These groups were the salvation of this market when the year of magical investing ended, and the super speculative stocks started coming back to earth, they’re still doing it, followed by the […]
  Dec 19, 2025
• Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes
  ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced the closing of a $20 million Series A financing. Proceeds will be used to advance the company’s lead program into Phase 2 clinical development for obesity and diabetes, as well as other programs in IND-enabling stage and early preclinical stage. The financing was led by Lapam Capital, with participation from Frees Fund and Riverhead Capital. “This Seri
  Dec 19, 2025
• Top Research Reports for NVIDIA, Netflix & Merck
  New research highlights NVIDIA's AI-driven growth, Netflix's ad-tier momentum and Merck's pipeline progress, while microcaps also make the cut.
  Dec 19, 2025
• Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
  RAHWAY, N.J., December 19, 2025--Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
  Dec 19, 2025
• Three Prominent Dividend Stocks To Consider
  As the U.S. stock market experiences a resurgence, with major indexes like the Nasdaq and S&P 500 seeing notable gains driven by tech shares, investors are keenly observing opportunities across various sectors. In this dynamic environment, dividend stocks stand out as a compelling option for those seeking consistent income streams alongside potential capital appreciation.
  Dec 19, 2025
• Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2
  MSD declines to exercise option for EVX-B2 developmentEvaxion is now able to out-license EVX-B2 to another partnerEvaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in preclinical studiesThere is no impact on Evaxion’s cash runway which extends to the second half of 2027 COPENHAGEN, Denmark, December 19, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has bee
  Dec 19, 2025
• Can Merck Successfully Steer Through the Upcoming Headwinds?
  MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.
  Dec 19, 2025
• Novo files for CagriSema approval; Merck and Pfizer’s trial win
  Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.
  Dec 19, 2025
• Nine Big Drugmakers Reach Pricing Deals With White House
  Nine pharmaceutical companies including Merck and GSK agreed to lower certain U.S. prices for their medicines in a new round of industry pacts with the Trump administration. The companies agreed to reduce U.S. prices on drugs to levels comparable with prices charged in other wealthy countries, which are generally much lower. Merck, for example, said it would make diabetes drugs Januvia and Janumet available to eligible American patients at a cash price that is 70% off the current list price through a direct-to-patient program.
  Dec 19, 2025
• Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump
  Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.
  Dec 19, 2025
• 3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
  J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
  Dec 18, 2025
• Merck (MRK) Rises Higher Than Market: Key Facts
  In the latest trading session, Merck (MRK) closed at $100.69, marking a +1.52% move from the previous day.
  Dec 18, 2025
• Does Merck KGaA’s Rebound Reflect Its True Value After AI Partnership And CEO Change News
  Wondering if Merck KGaA is a bargain hiding in plain sight or a value trap at €118.85? This article unpacks what the market is really pricing in. The stock has slipped 0.2% over the last week, but is up 6.4% over the past month, even though it remains down 15.3% year to date and 12.6% over the last year. That rebound has come as investors refocus on Merck's diversified footprint across healthcare, life science, and electronics, and its ongoing investments into high growth areas like...
  Dec 18, 2025
• Micron upgraded, PayPal downgraded: Wall Street's top analyst calls
  Micron upgraded, PayPal downgraded: Wall Street's top analyst calls
  Dec 18, 2025
• Here Are Thursday’s Top Wall Street Analyst Research Calls: Digital Realty, GE Vernova, Micron Technology, Merck & Co., Rivian, United Airlines, and More
  Pre-Market Stock Futures: Futures are trading higher on Thursday as we grind closer to the Christmas holiday, which is just a week off now. The song remains the same for the AI/Datacenter trade, and participants are finding it’s going to be a bit tougher here at the end of the year than in the last ... Here Are Thursday’s Top Wall Street Analyst Research Calls: Digital Realty, GE Vernova, Micron Technology, Merck & Co., Rivian, United Airlines, and More
  Dec 18, 2025
• Merck & Co., Inc. (MRK) Sees Mixed Analyst Views as Europe Advances WINREVAIR Review
  We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Merck & Co., Inc. is among the most undervalued stocks. On December 12, 2025, Morgan Stanley analyst Terence Flynn reiterated an Equal Weight rating on MRK and raised the price target from $100 to $102 in a research note to […]
  Dec 17, 2025
• BofA Turns More Positive on Merck (MRK) Pipeline
  Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best Dogs of the Dow to Invest in. On December 15, BofA raised its price target on Merck & Co., Inc. (NYSE:MRK) to $120 from $105 and kept a Buy rating. The analyst said the stock is starting to look more appealing as the pipeline […]
  Dec 17, 2025
• FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug
  Adagene jumps 13.8% after the FDA grants Fast Track Status to muzastotug with pembrolizumab for MSS metastatic colorectal cancer.
  Dec 17, 2025
• Big Pharma stocks 'way undervalued,' says market expert
  <body><p>STORY: Coons noted that although regulatory changes have "weighed on some stocks within healthcare... we still like the weight-loss theme, particularly around Lilly."</p><p>The global obesity market has surged in recent years on strong demand for GLP-1-based drugs like Lilly's blockbuster drug Zepbound.</p><p>Lilly also produces Kisunla, a drug to slow Alzheimer's.</p><p>"When you're looking at Big Pharma, they're just way undervalued right now relative to the rest of the market," said Coons, who added, "we do like Merck as well."</p></body>
  Dec 17, 2025
• Merck (MRK): Valuation Check After Promising KEYTRUDA Plus Padcev Phase 3 Bladder Cancer Results
  Merck (MRK) just cleared an important clinical hurdle, reporting strong Phase 3 KEYNOTE B15 results showing that KEYTRUDA plus Padcev improved survival outcomes for muscle invasive bladder cancer patients compared with standard chemotherapy and surgery. See our latest analysis for Merck. Despite the headline grabbing oncology wins and regulatory progress on drugs like Winrevair, Merck’s 90 day share price return of 21.11 percent has not yet translated into outsized long term total shareholder...
  Dec 17, 2025
• Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight
  DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
  Dec 17, 2025
• KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
  RAHWAY, N.J., December 17, 2025--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The trial showed KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv), given as neoadjuvant and adjuvant treatment (before and after surgery), demonstrated a statistically signifi
  Dec 17, 2025
• The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now
  It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.
  Dec 17, 2025
• Merck (MRK) Price Target Lifted at Morgan Stanley as Biopharma Outlook Improves
  Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Blue-Chip Stocks with Growing Dividends. On December 12, Morgan Stanley lifted its price target on Merck & Co., Inc. (NYSE:MRK) to $102 from $100. The firm kept an Equal Weight rating on the stock. In its 2026 outlook for the biopharma space, the firm […]
  Dec 16, 2025
• Eli Lilly or Merck: Where Should Investors Put Their Money?
  LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.
  Dec 16, 2025
• Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
  Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated muzastotug, in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD
  Dec 16, 2025
• Sector Update: Health Care Stocks Retreat Late Afternoon
  Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index falling 1.6% and
  Dec 16, 2025
• Is Merck Still Attractive After Oncology Pipeline Progress And Strong Five Year Share Price Gains
  If you are wondering whether Merck is still attractively priced today, or if the market has already priced in much of the potential upside, this is a good place to dig into what the numbers may indicate about its value. Merck’s share price is around $100.26, with gains of 1.3% over the last week, 7.9% over the last month, and 55.4% over five years. These moves highlight both resilience in the stock and changing expectations around its long term growth and risk profile. Recent headlines have...
  Dec 16, 2025
• Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
  The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries having received full regulatory approvals including the United States Futility analysis remains on track for the first quarter of CY2026 and completion of patient enrolment in the third quarter of CY2026 SYDNEY, AUSTRALIA, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: I
  Dec 16, 2025
• Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026?
  Each company has a bullish case, but three stand out as great long-term buys.
  Dec 16, 2025
• Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast
  Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver.
  Dec 16, 2025
• BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?
  BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.
  Dec 15, 2025
• LGND: 2025 Analyst Day
  By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its 2025 analyst day on December 9 th , 2025, at the Harvard Club in New York City. The morning presentations highlighted the company’s achievements for 2025 and looked ahead to 2026, providing financial guidance for the next year. Details of the event are included in a press
  Dec 15, 2025
• Merck Poised for Mid-Single-Digit Revenue Growth in Fiscal 2026, BofA Says
  Merck (MRK) is expected to deliver mid-single-digit revenue growth in fiscal 2026 driven primarily b
  Dec 15, 2025
• MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH
  Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.
  Dec 15, 2025
• Biotech Bill Bundled in Pentagon Spending Plan May Worsen Pharma’s Patent Cliff Dilemma
  The next few years of projected revenues in the pharma space have more holes in them than industry CEOs’ favorite golf courses.
  Dec 15, 2025
• Merck's (NYSE:MRK) Upcoming Dividend Will Be Larger Than Last Year's
  Merck & Co., Inc.'s ( NYSE:MRK ) dividend will be increasing from last year's payment of the same period to $0.85 on...
  Dec 14, 2025
• Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?
  Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.
  Dec 14, 2025
• 2 Mega-Cap Stocks with Exciting Potential and 1 We Ignore
  Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.
  Dec 12, 2025
• Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
  RAHWAY, N.J., December 12, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of an expanded indication for WINREVAIR™ (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II, III, and IV based on the Phase 3 ZENITH study. The cu
  Dec 12, 2025
• Does WINREVAIR’s CHMP-Backed Label Expansion Shift The Bull Case For Merck (MRK)?
  In early December 2025, Merck reported that the EMA’s Committee for Medicinal Products for Human Use recommended expanding WINREVAIR’s EU indication to cover adults with pulmonary arterial hypertension in WHO Functional Class II, III and IV, based on Phase 3 ZENITH data in high‑risk patients. This positive opinion, following recent U.S. label updates, strengthens WINREVAIR’s profile as a first‑in‑class activin signaling inhibitor and could broaden its clinical and commercial reach in severe...
  Dec 12, 2025
• Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?
  Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
  Dec 12, 2025
• Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
  BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
  Dec 12, 2025
• Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026
  They could grow into their valuation over the next few years.
  Dec 12, 2025
• Merck (MRK) Laps the Stock Market: Here's Why
  Merck (MRK) closed at $99.01 in the latest trading session, marking a +1.42% move from the prior day.
  Dec 11, 2025
• Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1
  ​Merck & Co., Inc. (NYSE:MRK) is one of the Cheap NYSE Stocks to Buy Now. On December 5, an analyst from Guggenheim raised the firm’s price target on Merck & Co., Inc. (NYSE:MRK) from $104 to $122 and maintained a Buy rating on the stock. ​A day earlier, on December 4, the company announced receiving […]
  Dec 11, 2025
• Why Analysts Think Merck Could Be Undervalued As Its Pipeline Story Evolves
  Merck's updated narrative now anchors to a slightly higher fair value estimate of about $106.62 per share, up from roughly $104.27, as analysts grow more confident in the depth and durability of its pipeline. With revenue growth expectations trimmed only marginally and the discount rate left effectively unchanged at around 6.96%, the shift reflects nuanced optimism rather than a wholesale rerating. Stay tuned to see how you can keep track of these incremental adjustments as the story around...
  Dec 11, 2025
• Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth
  ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.
  Dec 11, 2025
• Merck (NYSE:MRK) Could Be A Buy For Its Upcoming Dividend
  It looks like Merck & Co., Inc. ( NYSE:MRK ) is about to go ex-dividend in the next four days. The ex-dividend date is...
  Dec 10, 2025
• Guggenheim Lifts PT on Merck & Co. (MRK) to $122 From $104
  Merck & Co., Inc. (NYSE:MRK) is one of the best pharma stocks to invest in. Guggenheim lifted the price target on Merck & Co., Inc. (NYSE:MRK) to $122 from $104 on December 5 while maintaining a Buy rating on the shares. The firm cited the inclusion of probability-adjusted revenues for Winrevair in the population investigated in […]
  Dec 10, 2025
• Immutep Limited (IMMP): Firm Reports Positive Data from Trials
  Immutep Limited (NASDAQ:IMMP) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. In mid-November, Immutep Limited (NASDAQ:IMMP) reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. The firm revealed that a Phase 2 study of efti in combination with radiotherapy and Merck’s Keytruda showed significant […]
  Dec 10, 2025
• 2 Pharmaceutical Stocks to Buy at a Discount
  Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.
  Dec 10, 2025
• Dividend Stocks for 2026: Where to Invest as the Market Cools
  These three dividend heavyweights offer attractive yields and upside potential heading into what could be an uncertain 2026.
  Dec 10, 2025
• MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?
  Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.
  Dec 9, 2025
• Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
  Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.
  Dec 9, 2025
• Global Market for Merkel Cell Carcinoma Driven by Key Players Like Merck & Bristol Myers Squibb
  The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly affecting older adults, is increasingly being treated with immune checkpoint inhibitors like Keytruda and Opdivo, which have revolutionized patient survival rates. The market faces challenges with the high cost of treatments impacting accessibility. Key players such as Merck, Bristol Myers Squibb, a
  Dec 9, 2025
• Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer
  MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).
  Dec 9, 2025
• BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research
  TORONTO, December 09, 2025--BenchSci, a leading provider of AI software for biopharma research and development, today announced a renewed two-year contract with Merck, known as MSD outside of the United States and Canada.
  Dec 9, 2025
• 1 Major Factor Behind the Healthcare Sector's Recent Surge
  Blockbuster drugs are a major driver of the growth of healthcare stocks.
  Dec 9, 2025
• Strategic Pharma Collaborations Propel RCC Market Growth
  The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The "Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi
  Dec 9, 2025
• Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump
  The company is finding ways to overcome the headwinds it will encounter in the medium term.
  Dec 9, 2025
• How Protein And Pets Drove Elanco Animal Health's Double-Digit Gain In 2025
  Elanco Animal Health CEO Jeff Simmons says the company is in the best position it's been in years. Elanco stock has surged in 2025.
  Dec 9, 2025
• Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning
  The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) is a popular income choice for retirees. The fund generates income by holding a portfolio of dividend-paying U.S. stocks selected for their financial strength and dividend consistency. The ETF tracks the Dow Jones U.S. Dividend 100 Index, which screens for companies with at least 10 consecutive years of ... Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning
  Dec 9, 2025
• These 2 High-Yield Dividend Stocks Are Some of the Safest Buys Right Now
  Merck and Duke Energy stand out as rare “safe yield” plays, pairing 3%+ dividends with solid earnings growth, reasonable payout ratios, and durable demand drivers in healthcare and regulated utilities.
  Dec 9, 2025
• Company News for Dec 8, 2025
  Companies in The News Are: WBD, NFLX, MRK, VSCO, NRG
  Dec 8, 2025
• Jim Cramer on Merck: “The People Who Run This Company Are Not Idiots”
  Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted the company’s strategic planning for when Keytruda loses patent protection. He commented: “The people who run this company are not idiots. They’ve long known that Keytruda would lose patent protection, so, for years, they’ve been […]
  Dec 8, 2025
• Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
  The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
  Dec 8, 2025
• Watch 5 Bigwigs in December After Double-Digit Returns Past Month
  Five market giants, CVNA, WMT, AMAT, FCX and MRK, delivered double-digit returns last month with more room to run in December.
  Dec 8, 2025
• Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.
  Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced that Kostas Biliouris has joined the firm as Managing Director on its Biotech Research Team. He will report to William (Bill) Bird, Director of Research, and be based in New York City.
  Dec 8, 2025
• Saskatchewan Adds CAPVAXIVE® to Publicly Funded Adult Immunization Program
  Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the province of Saskatchewan has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to its publicly funded adult immunization program. This addition supports increased access to pneumococcal immunization for eligible adults in accordance with the provincial eligibility criteria.
  Dec 8, 2025
• Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?
  After a long hiatus, why are the bulls so willing to buy in now?
  Dec 7, 2025
• Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
  With yields between 3.4% and 6.8%, you'll need to think carefully about the highest yields in the Dow before you buy them.
  Dec 7, 2025
• US Loses Financing Edge as Asia Borrows in Euros: Credit Weekly
  Asia Pacific borrowers increased euro‑denominated issuance to a record 23% of the total across both currencies this year, up six percentage points from 2024, according to Bloomberg-compiled data. Multiple Asian deals ranked as the most oversubscribed in Europe’s publicly syndicated debt market during their launch week, the data showed. US dollar deals still make up the majority of financing deals, and borrowing in the greenback is up 29% by Asian issuers this year.
  Dec 6, 2025
• Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”
  Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]
  Dec 6, 2025
• Do These 3 Healthcare Stocks Need a Checkup?
  These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?
  Dec 5, 2025
• Is This Pharmaceutical Giant a Buy After a Major Acquisition?
  The rebound is well underway.
  Dec 5, 2025
• These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them?
  After tepid performances throughout most of 2025, these stocks are showing some upward momentum.
  Dec 5, 2025
• TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
  Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled solutions for injectable medications, has entered into a distribution partnership with Salomo Executive, a leading healthcare logistics and consultancy company based in the Netherlands. This collaboration...
  Dec 5, 2025
• Merck & Co., Inc. (MRK): A Bull Case Theory
  We came across a bullish thesis on Merck & Co., Inc. on Darius Dark Investing’s Substack. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc.’s share was trading at $101.03 as of December 2nd. MRK’s trailing and forward P/E were 13.47 and 10.83 respectively according to Yahoo Finance. Merck & Co. (MRK) […]
  Dec 4, 2025
• Can Merck's New Products Aid Growth as Keytruda LOE Test Looms?
  MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.
  Dec 4, 2025
• Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel
  CARMEL, Ind. & LONDON, December 04, 2025--Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel
  Dec 4, 2025
• FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
  RAHWAY, N.J., December 04, 2025--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) has granted a conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution). This innovative product is in the newest class of parasiticides known as isoxazolines. The pour-on solution is effective for the prevention and treatment of infestati
  Dec 4, 2025
• Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
  Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck to refrain from distributing and offering Keytruda SC in Germany.
  Dec 4, 2025
• The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch.
  RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking to make deals.
  Dec 4, 2025
• Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case
  The Munich Regional Court ruled there was imminent infringement for Merck & Co.’s Keytruda SC in Germany related to Halozyme’s MDASE patents in Europe, the San Diego company said.
  Dec 4, 2025
• Merck (MRK): Revisiting Valuation After a 22% One-Month Share Price Surge
  Merck (MRK) has quietly pulled ahead of many pharma peers, with the stock climbing about 22% over the past month and 20% in the past 3 months, drawing fresh attention to its valuation. See our latest analysis for Merck. That surge comes after a more muted stretch, with the share price now at $101.03 and a modest year to date share price return. However, a solid five year total shareholder return suggests long term holders have still done well. If Merck’s move has you rethinking opportunities...
  Dec 3, 2025
• Why Merck (MRK) is a Top Growth Stock for the Long-Term
  Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
  Dec 2, 2025
• 1 Value Stock to Target This Week and 2 We Question
  The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
  Dec 2, 2025
• Vaccine stocks brace for shock waves at this week’s ACIP meeting
  Investing.com -- Bernstein warned in a note Tuesday that “shock waves are expected at the ACIP meeting this week,” citing a series of unusual developments that could have implications for Merck, Pfizer and Moderna.
  Dec 2, 2025
• Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure
  Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.
  Dec 2, 2025
• Has Merck’s Valuation Shifted After Key Pipeline Updates and an 18% Stock Jump?
  Ever wondered if Merck’s current share price actually reflects its real worth? You’re not alone, and uncovering value can make all the difference for your portfolio. Merck’s stock has jumped 18.4% over the last 30 days, even though it’s dipped 3.6% over the last week. This shows just how quickly market sentiment can shift. This recent volatility comes as investors react to a wave of positive pipeline updates and strategic partnership announcements, which have fueled fresh optimism about...
  Dec 2, 2025
• Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
  Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (
  Dec 2, 2025
• Nanopharmaceuticals Research Report 2025: Market to Reach $104.58 Billion by 2030, Driven by Rising Chronic Disease Burden and Growing Investment in Regenerative Medicine and Nanotechnology Drugs
  The nanopharmaceuticals market presents opportunities in addressing chronic diseases through enhanced targeted therapies and bioavailability. Personalization in treatments, particularly in oncology, is a key trend. However, high R&D costs and regulatory hurdles pose challenges. Key players include Merck, Pfizer, and Novartis. Nanopharmaceuticals Market Nanopharmaceuticals Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Nanopharmaceuticals Market - Global Industry Size, Share, Trends, Oppor
  Dec 2, 2025
• Here's Why Merck (MRK) is a Strong Momentum Stock
  Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
  Dec 1, 2025
• UK and US agree zero tariff deal on pharmaceuticals
  Import taxes on medicines and treatments will remain at 0% for three years, the UK Government said.
  Dec 1, 2025
• APPLE PAY TO ATMS, FASHION TO FITNESS, AND GIFT IDEAS FOR EVERYONE, (RED) SOLVES HOLIDAY SHOPPING FOR THE SEASON
  Marking World AIDS Day (December 1), and Giving Tuesday (December 2), (RED), the organization co-founded by Bono and Bobby Shriver to fight AIDS, announces today the return of 'The (RED) Holiday Edit'. The campaign runs through the holidays, ahead of (RED)'s 20th anniversary year in 2026 and with more than $800 million raised for the Global Fund thanks to extraordinary partners, people and products.
  Dec 1, 2025
• Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
  RAHWAY, N.J., December 01, 2025--Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
  Dec 1, 2025
• Treasuries Lead Global Bond Selloff Amid Corporate Supply Surge
  Yields climbed by at least five basis points to the highest levels in about a week. The move accelerated during the US morning — led by long-maturity tenors, which ended about eight basis points higher — after Merck & Co. slated the largest of a slew of corporate bond offerings that totaled $15.8 billion.
  Dec 1, 2025
• Buffer Preparation Market Trends & Forecasts Report 2025-2035 Featuring Asahi Kasei, Avantor, Canvax, Danaher, GE, HOPAX, Merck, Prepared Biologics, Sartorius, Sepragen, Thermo Fisher Scientific, ZETA
  Key opportunities in the buffer preparation market include expanding demand for advanced buffer systems in biopharma production, increasing preference for outsourcing to reduce costs, and growth potential in reusable equipment and liquid formulations. North America remains dominant, while Asia-Pacific exhibits high growth potential. Scale of Operation Scale of Operation Buffer Service Providers Buffer Service Providers Buffer Manufacturing Systems Buffer Manufacturing Systems Dublin, Dec. 01, 20
  Dec 1, 2025
• Stock Market Today: Indexes End Lower; Moderna Dives On FDA Memo; Synopsys, Nvidia Jump (Live Coverage)
  The Dow fell on the stock market today. Moderna skidded after an FDA memo linked Covid vaccines to deaths. A gold stock cleared an entry.
  Dec 1, 2025
• Wells Fargo Upgrades Merck (MRK) to Overweight, Raises Price Target to $125
  Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Boring Dividend Stocks to Buy. On November 24, Wells Fargo upgraded⁠ Merck & Co., Inc. (NYSE:MRK) to Overweight from Equal Weight, raising its price target to $125 from $90, according to a report by The Fly. The fi‍rm cited rece‌nt business developments, pipeline advance‌ment‍s, […]
  Nov 30, 2025
• 3 Non-AI Stocks to Buy: MRK, UPS, CVX
  There are plenty of potential winners outside the world of AI.
  Nov 30, 2025
• These Underrated Companies Could Be "Training-Wheels" Stocks for Long-Term Wealth Builders
  If you are thinking in decades and not days, this trio of dividend stocks could be the perfect starting point for your fledgling portfolio.
  Nov 30, 2025
• Jim Cramer Says He is “Particularly Fond” of Johnson & Johnson
  Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer discussed, along with the need for diversification. Cramer highlighted that he is fond of the stock, as he said: “You could own JNJ and Merck with their incredible franchises. You know what? I’m actually particularly fond of JNJ right now. They’re spinning off their […]
  Nov 29, 2025
• Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%?
  The struggling pharmaceutical giant is showing signs of life.
  Nov 29, 2025
• JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030
  JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.
  Nov 28, 2025
• Western Digital and 6 More Stocks That Survived the AI Selloff and Could Be Worth Buying
  Investors will be weighing up how to shield their portfolios in case the rebound loses steam. These stocks look tempting.
  Nov 28, 2025
• Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
  Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.
  Nov 27, 2025
• Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
  Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
  Nov 27, 2025
• AstraZeneca or Merck: Which Oncology Giant Has the Edge?
  AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.
  Nov 27, 2025
• Follicular Lymphoma Market Trends, Opportunities, Growth Challenges and Competitive Intelligence 2025-2035
  The global follicular lymphoma market is witnessing growth due to advancements in targeted therapies and immunotherapies. Follicular lymphoma, an indolent form of non-Hodgkin lymphoma, often presents challenges like relapse and treatment resistance, underscoring the need for novel treatment strategies. Innovative therapies such as monoclonal antibodies and CAR T-cell therapies are enhancing patient outcomes by providing more precise and less toxic options compared to traditional chemotherapy. Ke
  Nov 27, 2025
• Why Merck (MRK) Is Up 9.6% After Pipeline Upgrade and Regulatory Wins and What's Next
  In the past week, Merck received a boost as Wells Fargo upgraded its rating, citing increased confidence in Merck’s drug pipeline and noting significant progress in regulatory approvals for new oncology and HIV treatments. A key insight is that analysts see Merck’s pipeline advancements and diversified business development as easing concerns about future revenue risks associated with Keytruda’s eventual loss of exclusivity. With fresh optimism about Merck’s product pipeline and recent...
  Nov 26, 2025
• BofA Raises Merck (MRK) Price Target to $105, Keeps Buy Rating
  Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Stocks to Buy for Medium Term. On November 17, BofA analyst Tim Anderson raised the firm’s price target on Merck & Co., Inc. (NYSE:MRK) to $105 from $98 and maintained a Bu⁠y ratin​g on the share‍s, as reported by The Fly. He‌ de​scribed the Cidara […]
  Nov 26, 2025
• Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks
  Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.
  Nov 26, 2025
• Hedge Funds Pile Into Health Stocks Leading Market in Rotation
  The S&P 500 Health Care Index is up 10% through Tuesday, outperforming the other 10 sectors in the benchmark for US stocks. Eli Lilly & Co. has surged 29% to become the first health company with a $1 trillion valuation. Regeneron Pharmaceuticals Inc., Merck & Co. and Biogen Inc. are all up at least 18% since the end of October.
  Nov 26, 2025
• Merck to Participate in the Citi 2025 Global Healthcare Conference
  RAHWAY, N.J., November 26, 2025--Merck to Participate in the Citi 2025 Global Healthcare Conference
  Nov 26, 2025
• How Analyst Views on Merck Are Evolving as Growth Prospects and Risks Shift
  Merck has seen its fair value estimate edge higher to $104.27, up from $102.33, following recent updates to its growth outlook. Analysts cite an improved revenue growth expectation and a small uptick in the discount rate as drivers for this modest price target increase. This reflects a balance of positive developments and evolving risks. Stay tuned to discover how you can monitor shifts in Merck's story as new information emerges. Analyst Price Targets don't always capture the full story...
  Nov 26, 2025
• Will Soft Gardasil Demand Continue to Dampen Merck's Top Line?
  MRK faces steep Gardasil declines as China and Japan demand soften, putting pressure on its vaccine portfolio.
  Nov 26, 2025
• Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
  RAHWAY, N.J., November 26, 2025--Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
  Nov 26, 2025
• Centers for Medicare & Medicaid Services Unveils $12 Billion Net Savings From Reduction in Drug Prices
  The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,
  Nov 26, 2025
• Stocks to Watch Wednesday: Dell, HP, Workday, Li Auto
  ↗️ Dell (DELL): The computer and software maker raised full-year guidance and forecast AI server shipments would more than double. Shares rose nearly 5% premarket. ↘️ HP (HPQ): The computer and printer maker plans to cut up to 10% of its workforce as it invests further in artificial intelligence.
  Nov 26, 2025
• U.S. Negotiates Lower Prices for Ozempic and 14 Other Drugs
  The U.S. government negotiated lower prices in the federal Medicare program for 15 high-selling medicines including Ozempic, widening an effort to rein in drug costs. The new prices, which will take effect in 2027, shave 38% to 85% off the list prices for drugs for diseases including asthma, cancer and diabetes. The reductions are estimated to save Medicare, the health-insurance program for the elderly, $12 billion.
  Nov 26, 2025
• 2 Dividend Stocks to Buy Now for Big Payout Growth Ahead
  Merck and Qualcomm combine strong cash flow with steady dividend growth, signaling potential for meaningful payout increases ahead.
  Nov 26, 2025
• Merck & Co. Stock: Is MRK Outperforming the Healthcare Sector?
  Merck has outperformed the healthcare sector over the past three months. Moreover, Wall Street analysts are moderately optimistic about its prospects.
  Nov 26, 2025
• 4 takeaways from pharma’s manufacturing boom
  As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.
  Nov 25, 2025
• Stocks making big moves yesterday: Meta, Tenet Healthcare, Wynn Resorts, Elevance Health, and Merck
  Check out the companies making headlines yesterday:
  Nov 25, 2025
• [Latest] Global Dairy Herd Management Market Size/Share Worth USD 15.23 Billion by 2034 at a 11.37% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
  [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Dairy Herd Management Market size & share revenue was valued at approximately USD 5.17 Billion in 2024 and is expected to reach USD 5.76 Billion in 2025 and is expected to reach around USD 15.23 Billion by 2034, at a CAGR of 11.37% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are DeLaval, Merck & Co. Inc
  Nov 25, 2025
• Variational AI Redefines Drug Discovery with Generative AI Platform, Secures Strategic Collaboration with Merck
  VANCOUVER, BC / ACCESS Newswire / November 25, 2025 /Variational AI, a leading innovator in generative artificial intelligence for drug discovery, is making headlines in biotech with a bold mission: to reinvent early-stage drug discovery using AI-native ...
  Nov 25, 2025
• Stock Market Today: Dow Climbs 664 Points, Revisits 47,000; Nvidia Falls As Palantir Rises (Live Coverage)
  The Dow Jones Industrial Average and other major indexes ended Tuesday with hefty gains, as investors saw weak economic data as supporting a decision by the Federal Reserve to lower interest rates in December. Nvidia and Advanced Micro Devices slid on the stock market today on a report that Meta Platforms will use Google's AI chips. The Dow closed up 1.4%, or 664 points, despite Nvidia's 2.6% drop.
  Nov 25, 2025
• Kelun, Merck tout ADC as potential first-line treatment in lung cancer
  The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential approval in the first-line setting.
  Nov 25, 2025
• Why Merck (MRK) Stock Is Trading Up Today
  Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 4.1% in the afternoon session after Wells Fargo upgraded the stock to "Overweight" from "Equal-Weight," citing confidence in the company's future.
  Nov 24, 2025
• Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
  RAHWAY, N.J., November 24, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company’s ongoing commitment to advancing clinical research in hematology across Merck’s expanding and diverse pipeline of investigational candidates
  Nov 24, 2025
• Merck upgraded at Wells Fargo as analyst sees ‘a future beyond Keytruda’
  Investing.com -- Merck shares received an upgrade at Wells Fargo, with analyst Mohit Bansa lifting the stock to Overweight and raising the price target to $125 per share in a note Monday, saying the firm “can see a future beyond Keytruda” as the company enters a catalyst-heavy stretch.
  Nov 24, 2025
• FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer
  Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.
  Nov 24, 2025
• Q3 Earnings Outperformers: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Stocks
  Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Merck (NYSE:MRK) and the best and worst performers in the branded pharmaceuticals industry.
  Nov 24, 2025
• Booking, Carvana upgraded: Wall Street's top analyst calls
  Booking, Carvana upgraded: Wall Street's top analyst calls
  Nov 24, 2025
• Urinary Tract Infection Treatment Market Competitor Analysis Report 2025: Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue
  The Urinary Tract Infection (UTI) Treatment Market is projected to grow from US$ 9.13 Billion in 2024 to US$ 11.64 Billion by 2033, at a CAGR of 2.73%. This expansion is driven by rising UTI prevalence, awareness of early diagnosis, and advancements in therapy. Key growth factors include aging populations, rising catheter-associated infections, and a growing female demographic. Innovative treatments like vaccines and probiotics are gaining traction amid antibiotic resistance. North America leads
  Nov 24, 2025
• Stock Market Today: Dow, Nasdaq End In Rally Mode; Tesla Surges On This Elon Musk AI Boast (Live Coverage)
  The Dow Jones index and the Nasdaq rise on the stock market today. Tesla jumps amid an AI boast by Elon Musk. Some health stocks test entries.
  Nov 24, 2025
• Here are Monday’s Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More
  Pre-Market Stock Futures: The shortened holiday week is here, and the futures are trading higher this morning. Most traders and investors are returning with a severe case of whiplash after the stock market posted some of the wildest swings we have seen this year last week. Skyrocketing after the NVIDIA Corp (NASDAQ: NVDA) earnings and ... Here are Monday’s Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More
  Nov 24, 2025
• Analysts Shift to Hold as Cidara’s (CDTX) Recent Acquisition Deal Caps Upside
  Cidara Therapeutics Inc. (NASDAQ:CDTX) is the top stock in our list of the hottest SMID-cap stocks so far in 2025 with a 717% share price surge year-to-date. Following the acquisition announcement by Merck & Co. Inc. (NYSE:MRK), Guggenheim analyst Seamus Fernandez downgraded his rating on Cidara Therapeutics from Buy to Neutral on November 17, according to […]
  Nov 23, 2025
• Looking For Yields: Merck, Altria, And Genuine Parts Are Consistent Moneymakers
  Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Merck, Altria, and Genuine Parts have rewarded shareholders for years and recently announced dividend increases. These ...
  Nov 22, 2025
• Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To $0.85
  Merck & Co., Inc.'s ( NYSE:MRK ) periodic dividend will be increasing on the 8th of January to $0.85, with investors...
  Nov 22, 2025
• Merck Recommends Rejection of Tutanota’s "Mini-Tender" Offer
  RAHWAY, N.J., November 22, 2025--Merck Recommends Rejection of Tutanota’s "Mini-Tender" Offer
  Nov 22, 2025
• This Medicare premium just crossed $200 a month for the first time. Here’s why.
  The 9.7% increase in the cost of Medicare Part B premiums for 2026 is due to several factors, including projected growth in Medicare Advantage and outpatient care next year
  Nov 22, 2025
• AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
  AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
  Nov 21, 2025
• Medtronic (MDT)’s CEO “is One of the Finest People,” Says Jim Cramer
  We recently published 13 Stocks That Crossed Jim Cramer’s Radar. Medtronic plc (NYSE:MDT) is one of the stocks Jim Cramer discussed. Medtronic plc (NYSE:MDT) is a medical technology company that makes and sells devices for cardiovascular, neuroscience, and surgical applications. Cramer has discussed the firm on a handful of occasions in 2025. One such discussion […]
  Nov 21, 2025
• PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
  Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.
  Nov 21, 2025
• Sector Update: Health Care Stocks Higher Late Afternoon
  Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index and the Health
  Nov 21, 2025
• The Zacks Analyst Blog Highlights Visa, Merck, Southern Company, Community Bancorp and Comstock
  V benefits from rising cross-border volumes and strong digital payments momentum as analysts spotlight broad performance drivers across key sectors.
  Nov 21, 2025
• GSK, Anaptysbio sue each other over Jemperli revenue
  As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding development of the cancer immunotherapy.
  Nov 21, 2025
• Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know
  A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to
  Nov 21, 2025
• FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
  RAHWAY, N.J., November 21, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who a
  Nov 21, 2025
• Stock Market Today: Dow Gains Nearly 500 Points After Whipsaw Action As Nvidia Finishes Lower (Live Coverage)
  Stock Market Today: The Dow Jones index rallied Friday after back-and-forth action. But Nvidia and Palantir couldn't pull ahead.
  Nov 21, 2025
• Here's Why Merck (MRK) is a Strong Value Stock
  The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
  Nov 20, 2025
• Merck's $3 Billion AI Gamble: Inside the Bold Bet to Crack Parkinson's
  With its pipeline under pressure, Merck turns to Valo Health's AI brainpower in a high-stakes neuroscience push
  Nov 20, 2025
• MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
  Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
  Nov 20, 2025
• Top Analyst Reports for Visa, Merck & Southern Company
  Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory pressures.
  Nov 20, 2025
• VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future
  A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia's life sciences ecosystem, higher-ed universities, and community colleges on October 31. This landmark public-private industry partnership commits $120 million of workforce inves
  Nov 20, 2025
• Sector Update: Health Care Stocks Softer Late Afternoon
  Health care stocks declined late Thursday afternoon with the NYSE Health Care Index and the Health C
  Nov 20, 2025
• Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)
  Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan‑Canadian Pharmaceutical Alliance (pCPA) for WINREVAIR® (sotatercept). The pCPA negotiates on behalf of the provinces, territories, and federal drug programs serving as a critical step in bringing WINREVAIR® closer to public reimbursement.
  Nov 20, 2025
• Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
  Shares in the biotech company have surged on news of a big pharma takeover.
  Nov 20, 2025
• Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
  The pharmaceutical giant's post-Keytruda plans continue to take shape.
  Nov 20, 2025
• Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
  Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions, including marketing, sales, commercial operations, market access, trade and business development.
  Nov 20, 2025
• This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.
  For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date. It’s a challenge that Bristol Myers Squibb is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022. Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.
  Nov 20, 2025
• 133-year-old drug company plans layoffs, files WARN notice
  Layoffs are increasing this year, and they're not limited to any one particular industry. We've previously seen high-profile layoffs from fast-growing technology stalwarts, including Amazon and Microsoft. Now, we've learned that Merck & Co., a 133-year-old drug manufacturer, also ...
  Nov 20, 2025
• Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership
  Valo will use its trove of patient records and biobank samples to pinpoint potential targets for Merck’s pipeline expansion.
  Nov 20, 2025
• Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
  MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
  Nov 19, 2025
• Merck (MRK): Is There Still Value After the Recent Share Price Rally?
  Merck (MRK) shares have ticked higher this week, catching the interest of investors who follow the big names in healthcare. The company's performance over the past month has been relatively steady. This stability invites a closer look at what might be driving sentiment. See our latest analysis for Merck. Merck’s momentum has picked up noticeably with a 1-month share price return of 13.7%, even as the year-to-date performance remains slightly negative. The stock’s 1-year total shareholder...
  Nov 19, 2025
• PFE- The Winner in the Metsera Bidding War
  Pfizer Inc. (PFE) finally topped Novo Nordisk (NVO) to buy Metsera after Novo raised its bid twice. Metsera’s crown jewel is MET-097i, a weekly and monthly injectable GLP-1 asset that’s about to begin Phase III development, writes John McCamant, editor of Medical Technology Stock Letter.
  Nov 19, 2025
• 2 Healthcare Stocks Worth Your Attention and 1 We Ignore
  Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 7.4% return has trailed the S&P 500 by 3.6 percentage points.
  Nov 19, 2025
• Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
  RAHWAY, N.J., November 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in adults with HIV-1 infection who had not previously received antiretroviral treatment (treatment-naïve) (MK-8591A-053). The success criterion for the primary efficacy hypothesis, as measured
  Nov 19, 2025
• Metrorrhagia Market Analysis Report 2025-2035, Profiles of Pfizer, Sandoz, Bayer, Actavis Pharma, Noven Pharmaceuticals, Theramex, Pantarhei Bioscience, AbbVie, Neurocrine Biosciences, Merck
  The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula
  Nov 19, 2025
• Astrocytoma Market Research and Forecast Report 2025-2035: Merck and Oblato are Spearheading Advancements in Drug R&D, Addressing the Growing Demand for Enhanced Therapeutic Options
  The global astrocytoma market is poised for significant growth, anticipated to achieve substantial valuation by 2025 and expanding at a healthy CAGR from 2025 to 2035. This expansion is driven by the rising prevalence of high-grade astrocytomas and the increasing demand for effective treatments, including innovative immunotherapies and targeted therapies. Key growth areas include emerging markets such as Asia-Pacific, Latin America, and the Middle East, where healthcare improvements are rapidly
  Nov 19, 2025
• SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
  GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the
  Nov 19, 2025
• European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
  RAHWAY, N.J., November 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved a new subcutaneous (SC), or under the skin, route of administration and a new pharmaceutical form (solution for injection) of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. KEYTRUDA SC™, as it will be marketed in the European Union (EU), [known as KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa-pmph) in the U.S.]
  Nov 19, 2025
• Why GRAIL Stock Could Be Biotech’s Next Big Breakout
  Explore insider buying signals, a promising cancer detection biotech, and why the American Dream is still achievable—even in a down market.
  Nov 19, 2025
• HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
  Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.
  Nov 19, 2025
• J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
  J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
  Nov 18, 2025
• Is Merck's Recent FDA Approval a Game Changer for Its Share Price?
  Thinking about whether Merck is a bargain or not? You’re not alone, plenty of investors are eager to know if now is the time to buy, hold, or stay away. Over the last month, Merck’s share price has jumped 9.5% and gained 7.0% this week alone, even though it’s still down 6.4% year-to-date. Recent headlines have highlighted Merck’s expanding drug pipeline and a new FDA approval, fueling a bit of optimism and helping offset earlier caution in the market. These developments have given more...
  Nov 18, 2025
• Merck Announces First-Quarter 2026 Dividend
  RAHWAY, N.J., November 18, 2025--Merck Announces First-Quarter 2026 Dividend
  Nov 18, 2025
• [Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)
  [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.
  Nov 18, 2025
• Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
  RAHWAY, N.J., November 18, 2025--Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF
  Nov 18, 2025
• Fanconi Anemia Market Research Report 2025-2035: Competitive Growth Driven by Rocket Pharmaceuticals, Foresee, Merck, and Abeona as Gene Therapy and CRISPR-Based Innovations Expand
  **Fanconi Anemia Market Growth Driven by Genetic Research and Healthcare Investments**Fanconi Anemia (FA) is a rare genetic disorder impacting bone marrow's ability to produce blood cells, leading to pancytopenia and increased cancer risk due to DNA repair defects. Although incurable, treatments like bone marrow transplants and gene therapy aim to manage FA's symptoms. The rising prevalence of genetic disorders and advancements in genetic research drive the FA market. Key players such as Rocket
  Nov 18, 2025
• Merck Stock Rises as Heart-Drug Test Offers Hope for Post-Keytruda Era
  The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.
  Nov 18, 2025
• Merck’s blockbuster-to-be cardiovascular drug scores in another heart study
  Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart in a study of adults with a common form of heart failure.
  Nov 18, 2025
• Merck Jumps On A Surprise Win; Why It Still Has A Long Road To Go
  Merck stock jumped Tuesday on a surprise win for its drug, sotatercept, in patients with pulmonary hypertension.
  Nov 18, 2025
• Drug Giant Merck Breaks Out Past New Buy Point; CME, Marathon Eye Entries
  Dow Jones drug giant Merck is breaking out past its latest buy point as the stock market volatility continues Tuesday.
  Nov 18, 2025
• Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 Billion
  J&J this year lost its patent exclusivity for Stelara, its longtime top-selling drug that treats psoriasis and inflammatory bowel disease.
  Nov 18, 2025
• Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything
  Merck's multi-billion-dollar acquisition of Cidara Therapeutics is a strategic move to secure a new era of growth with a high-potential antiviral asset.
  Nov 18, 2025
• MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
  Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.
  Nov 17, 2025
• MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
  Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
  Nov 17, 2025
• Goldman Sachs on brink of best M&A performance in 24 years
  Goldman Sachs is vying to capture its biggest share of the deals market in almost a quarter of a century, with Wall Street’s dominant investment...
  Nov 17, 2025
• Sector Update: Health Care Stocks Softer Late Afternoon
  Health care stocks were decreasing late Monday afternoon with the NYSE Health Care Index and the Hea
  Nov 17, 2025
• Cidara downgraded on Wall Street after Merck agrees to $9.2 billion buyout
  Investing.com -- Cidara Therapeutics was hit with broad downgrades after Merck agreed to buy the company for $221.50 a share in a deal valued at about $9.2 billion.
  Nov 17, 2025
• Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors
  SAN DIEGO, November 17, 2025--Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors
  Nov 17, 2025
• Solve lines up $120M to push ADCs into further testing
  The startup, which is backed by a dozen investors including Merck & Co., claims its novel “linkers” can help address some of the issues limiting the potential of earlier ADCs.
  Nov 17, 2025
• Cidara (CDTX) Climbs 105% on $9.2-Billion Merger with Merck
  We recently published 10 Market Movers That Made Millionaires in a Week. Cidara Therapeutics Inc. (NASDAQ:CDTX) is one of the best-performing stocks of the past trading week. Cidara Therapeutics soared by more than 100 percent week-on-week, as investors repositioned portfolios following news that it is set to be acquired by Merck Co. for $9.2 billion. […]
  Nov 16, 2025
• Companies Like Marks Electrical Group (LON:MRK) Are In A Position To Invest In Growth
  Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
  Nov 15, 2025
• Cidara Therapeutics (CDTX) Skyrockets 105% on Merck $9.2-Billion Acquisition Bid
  We recently published Lackluster Market? Not for These 10 Soaring Stocks. Cidara Therapeutics, Inc. (NASDAQ:CDTX) is one of the best-performing stocks on Friday. Cidara Therapeutics soared to nearly a decade high on Friday, as investors gobbled up shares following news that it is set to be acquired by pharmaceutical giant Merck for $9.2 billion. At […]
  Nov 15, 2025
• Merck to buy Cidara for $9.2B, Netflix nears 10-for-1 stock split
  Yahoo Finance host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute, including tech names Nvidia (NVDA), Tesla (TSLA), and Broadcom (AVGO) in recovery mode from Thursday's tech sell-off, Merck's (MRK) plans to buy Cidara Therapeutics (CDTX) in a deal worth up to $9.2 billion, and Netflix (NFLX) prepares to execute its 10-for-1 stock split. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.
  Nov 14, 2025
• Dow Drops For Second Day Amid Uncertainty Around December Rate Cut
  The Dow Jones Industrial Average fell Friday amid growing anxiety around the Federal Reserve's next
  Nov 14, 2025
• US Equity Indexes Mixed Amid Technology Rebound
  US equity indexes were mixed ahead of Friday's close amid selective dip-buying in technology and inf
  Nov 14, 2025
• Sector Update: Health Care Stocks Ease Late Afternoon
  Health care stocks fell late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Hea
  Nov 14, 2025
• Top Midday Stories: Merck to Acquire Cidara Therapeutics for $9.2 Billion; Walmart Names John Furner as CEO
  The S&P 500 and Nasdaq Composite rose in midday trading, erasing earlier declines, and the Dow Jones
  Nov 14, 2025
• US Equity Indexes Mixed as Technology Rebound Helps Lift Nasdaq, S&P 500
  US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec
  Nov 14, 2025
• Equities Mixed Intraday as Data Delays Further Diminish Fed Rate Cut Bets
  US benchmark equity indexes were mixed intraday as the odds of a Federal Reserve rate cut continued
  Nov 14, 2025
• RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
  ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today congratulated its former client, Cidara Therapeutics, on its acquisition ...
  Nov 14, 2025
• Top Stock Movers Now: StubHub, DoorDash, Netflix, and More
  Major U.S. equities indexes were mixed Friday afternoon, following a sharp decline Thursday fueled by a selloff of tech stocks.
  Nov 14, 2025
• Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal
  Cidara Therapeutics shares doubled, and then some, on Friday after Merck agreed to buy the biotech company for $9.2 billion.
  Nov 14, 2025
• Health Care Roundup: Market Talk
  Gain insight on bidding wars in the pharmaceuticals sector, Novo Nordisk and more in the latest Market Talks covering the health care sector.
  Nov 14, 2025
• This Biotech's Stock Price More Than Doubled on Friday. Here's Why.
  Merck agreed to pay $9.2 billion to purchase Cidara Therapeutics, looking to cash in on the firm's experimental flu treatment.
  Nov 14, 2025

MRK Reviews

• TradeFrenzy

  Dec 29, 2025

  $MRK Big pharma's best-kept secret... for a reason.

  Sell

• ShortAndProud

  Dec 28, 2025

  $MRK In the game for the long haul, ready to flex those muscles!

  Buy

• WallStreetWolf

  Dec 28, 2025

  $MRK This company's got more science up its sleeve than a mad scientist at a potion convention—seriously impressive stuff!

  Buy

• DiamondHands

  Dec 27, 2025

  $MRK This company is like your science teacher who actually knows their stuff—making the world a healthier place one experiment at a time!

  Buy

• MemeInvestor

  Dec 27, 2025

  $MRK This stock is like the dad who always has your back—solid, dependable, and probably with some dad jokes up its sleeve!

  Buy

• MarketNomad

  Dec 26, 2025

  $MRK Once a giant, now just clinging to past glory.

  Sell

• YieldHunter

  Dec 26, 2025

  $MRK As a leader in the pharmaceutical industry, this company continues to push boundaries in research and development, paving the way for future advancements.

  Buy

• EarningsSync

  Dec 24, 2025

  $MRK In this rapid-fire pharmaceutical landscape, one misstep could lead to a fall from grace. Investors are biting their nails as they wait for the next drug approval or setback. The stakes have never been higher!

  Sell

• WallStreetWraith

  Dec 24, 2025

  $MRK Pharmaceutical titan? More like a pill-popping disaster.

  Sell

• TickerTyrant

  Dec 24, 2025

  $MRK Still waiting for this one to impress anyone.

  Sell

• TradeHex

  Dec 23, 2025

  $MRK As a leader in pharmaceuticals, this company continues to push the boundaries of medical innovation. Its strong pipeline and commitment to research and development indicate a solid presence in a competitive market.

  Buy

• PortfolioFreak

  Dec 22, 2025

  $MRK The pharmaceutical arena is buzzing with both promise and peril; each breakthrough can flip the script but watch out for pitfalls—all eyes are on you!

  Buy

• WallStreetRogue

  Dec 22, 2025

  $MRK In the pharmaceutical race, innovation is key! Will this giant continue to lead the charge, or will it stumble as competitors gain ground? The clock is ticking!

  Sell

• MarketGlitch

  Dec 21, 2025

  $MRK This giant’s market movements are like a slow-motion train wreck. Will they turn it around or continue the downward spiral? The anxiety is unbearable!

  Sell

• TradeSaber

  Dec 21, 2025

  $MRK Making moves in the health game, watch out for the comeback!

  Buy

• TickerTrickster

  Dec 21, 2025

  $MRK Pharma power player, healing the game, ain't slowing down!

  Buy

• BullishVanguard

  Dec 21, 2025

  $MRK Just another overhyped pharma with questionable ethics.

  Sell

• FinTechFrost

  Dec 20, 2025

  $MRK Merck sounds like the name of a wizard that brews potions for profit. Let’s see if their magic works in the market!

  Buy

• QuantAssault

  Dec 20, 2025

  $MRK This company could probably cure your boredom, assuming you have a subscription to their stock reports!

  Buy

• CashCombo

  Dec 20, 2025

  $MRK With medications that even your doctor raves about, they’re basically the fairy godmother of the pharmaceutical world. Who wouldn't want a sprinkle of that magic?

  Buy

• TradeMatrix

  Dec 20, 2025

  $MRK Big pharma is under the spotlight, and every move counts. The potential for breakthrough treatments is thrilling, but one misstep could mean disaster. It's a high-stakes game!

  Buy

• MarginDagger

  Dec 19, 2025

  $MRK A leader in pharmaceuticals, this company continues to drive innovation in drug development. Their extensive research pipeline and commitment to enhancing health outcomes make them a formidable entity in the healthcare sector.

  Buy

• MarketWolf

  Dec 18, 2025

  $MRK Strong performance reports have analysts buzzing, but looming patent expirations could spell trouble. Navigating the ups and downs of the pharmaceutical landscape is like walking a tightrope. One misstep could lead to a fall.

  Sell

• BullRaid

  Dec 18, 2025

  $MRK The pharmaceutical giant forgot how to be a giant.

  Sell

• RiskAssassin

  Dec 18, 2025

  $MRK A titan in pharmaceuticals, yet the competition lurks around every corner! With every new treatment and patent, the stakes get higher and the tension thickens!

  Buy

• BullishBard

  Dec 18, 2025

  $MRK The only prescription here is more fun with stocks! Not a doctor, but I feel a good vibe!

  Buy

• StockSpecter

  Dec 17, 2025

  $MRK Just another overhyped pharma company with mediocre innovation.

  Sell

• FiscalEngine

  Dec 17, 2025

  $MRK A leader in the pharmaceutical sector, this firm has a diverse portfolio that consistently delivers groundbreaking products. Its strong commitment to research and development suggests a promising outlook for sustained growth.

  Buy

• TradeSaber

  Dec 17, 2025

  $MRK Big pharma flexin' hard, always got that steady hustle!

  Buy

• YOLOHold

  Dec 16, 2025

  $MRK Classic powerhouse, steady as they come, you know the drill!

  Sell

• BullRaid

  Dec 16, 2025

  $MRK Big pharma, small value; your health won't save this one.

  Sell

• FiscalFury

  Dec 16, 2025

  $MRK This one is like the cool science kid who always has the right answers in class. Who doesn’t love a genius?

  Buy

• MarketReaper

  Dec 16, 2025

  $MRK This giant is like that friend who always has the best snacks – you just know they're good for the long haul!

  Buy

• TickerTrickster

  Dec 16, 2025

  $MRK This one's got the cure for your portfolio blues, trust me!

  Buy

• ChartPilot

  Dec 15, 2025

  $MRK With groundbreaking drugs in the pipeline, the stakes are incredibly high! Any setback could mean disaster, and every competitor is breathing down their neck. It’s a nerve-racking race against time!

  Buy

• StonkSlayer

  Dec 15, 2025

  $MRK This stock is like a superhero—always swooping in to save the day when the market’s in trouble!

  Buy

• BullRunBoss

  Dec 15, 2025

  $MRK This company is like your favorite medicine—always there when you need it. Just don't forget to take it with breakfast!

  Buy

• DividendDegen

  Dec 15, 2025

  $MRK This one's got the meds that keep the game strong, feelin' good vibes all around!

  Buy

• MissionOverlord

  Dec 15, 2025

  $MRK Pharma strong, they got the cure for what ails ya.

  Buy

• ChartCrusher

  Dec 14, 2025

  $MRK Pharmaceuticals: great for profits, not so much for ethics.

  Sell

• OptionOutlaw

  Dec 14, 2025

  $MRK Major selloff risk looming.

  Sell

• StonkZombie

  Dec 14, 2025

  $MRK Classic move here, can't sleep on this heavyweight!

  Buy

• TraderFury

  Dec 13, 2025

  $MRK Uptrend looks clean and sustainable.

  Buy

• BullRunBoss

  Dec 13, 2025

  $MRK This company is like a trusty calculator; always there when you need it, but still can't help with your existential math questions.

  Buy

• VolatileViking

  Dec 13, 2025

  $MRK Think of this stock as the wise Yoda of the industry—full of knowledge and always teaching us the ways of the force!

  Buy

• CapitalHex

  Dec 13, 2025

  $MRK Continuation pattern looks healthy.

  Buy

• ProfitVortex

  Dec 13, 2025

  $MRK Supply overwhelming demand.

  Sell

• CashMeOutside

  Dec 13, 2025

  $MRK Big pharma's still flexin', don’t sleep on the magic!

  Buy

• MarketReaper

  Dec 12, 2025

  $MRK Short sellers gaining confidence.

  Sell

• CapitalHex

  Dec 12, 2025

  $MRK Multi-day uptrend continuation expected.

  Buy

• WallStreetVandal

  Dec 12, 2025

  $MRK Big pharma is where innovation goes to die slowly.

  Sell

• BullRunBoi

  Dec 12, 2025

  $MRK Bullish continuation expected.

  Buy

• TradePredator

  Dec 11, 2025

  $MRK Asset looks fundamentally weak.

  Sell

• StonkKnight

  Dec 11, 2025

  $MRK Market participants showing confidence.

  Buy

• BullishVanguard

  Dec 11, 2025

  $MRK Very poor structure forming.

  Sell

• RiskRaider

  Dec 11, 2025

  $MRK Weak structure offering no support.

  Sell

• ShortSavior

  Dec 10, 2025

  $MRK Big pharma with big problems—good luck defending that.

  Sell

• MarginMarauder

  Dec 10, 2025

  $MRK This one’s like that friend who always brings the best snacks to the party. They’ve got the cure for what ails you, and then some!

  Buy

• BullRunBandit

  Dec 9, 2025

  $MRK Big dog in the pharma scene, always got somethin' cookin', you know?

  Buy

• OptionCipher

  Dec 9, 2025

  $MRK The pressure cooker of the pharmaceutical world! With so many variables at play, it's a headache trying to predict where this stock will land. One misstep, and the stakes could skyrocket!

  Sell

• IndexPredator

  Dec 9, 2025

  $MRK Pharmaceutical companies are always under a microscope; can they continue innovating while facing regulatory hurdles? The stakes have never been higher!

  Buy

• HODLWarrior

  Dec 8, 2025

  $MRK Pharma giant flexin', but watch out for those ups and downs!

  Sell

• ChartNomad

  Dec 8, 2025

  $MRK When the pipeline news dropped, it sent ripples across the market! Investors are either thrilled or terrified, and the pressure is mounting as everyone holds their breath for the next big announcement.

  Buy

• HoldTheLine

  Dec 8, 2025

  $MRK Big pharma flexin' on the competition, holdin' it down.

  Buy

• QuantSpecter

  Dec 7, 2025

  $MRK In the high-stakes pharmaceutical arena, this company is navigating crucial challenges that could redefine its path. Will they overcome hurdles, or are we watching a slow decline?

  Sell

• BullBrawler

  Dec 6, 2025

  $MRK They might have good drugs, but their stock feels sick.

  Sell

• BullRunBoss

  Dec 6, 2025

  $MRK This stock is like the cool kid in school who always has the latest trends—everyone wants to hang out with it!

  Buy

• HODLzilla

  Dec 6, 2025

  $MRK Solid player in the field, they ain't goin' nowhere!

  Buy

• CapitalCreep

  Dec 6, 2025

  $MRK Upside breakout probability increasing.

  Buy

• StonkZombie

  Dec 6, 2025

  $MRK Price discovery to the upside next.

  Buy

• QuantSpecter

  Dec 4, 2025

  $MRK In a fluctuating market, this pharmaceutical giant is trying to stay ahead. Will their pipelines deliver when the pressure is on? It's a race against time and innovation.

  Buy

• ShortSqueezeX

  Dec 4, 2025

  $MRK Making medicines that work faster than my Wi-Fi during a storm—now that’s some serious magic!

  Buy

• FiscalEngine

  Dec 4, 2025

  $MRK A leader in pharmaceuticals, this company has a history of strong performance driven by its diverse range of life-saving medications. Ongoing research and development efforts promise to ensure its relevance and growth.

  Buy

• OptionNomad

  Dec 4, 2025

  $MRK In the ever-evolving pharmaceutical landscape, this stock is caught in a tug-of-war between innovation and regulation. Each announcement could either propel it to new heights or lead to unforeseen setbacks!

  Buy

• TradeSaber

  Dec 4, 2025

  $MRK Big pharma’s still hustlin’, stacking paper like it’s nothin’.

  Sell

• MarketSavage

  Dec 4, 2025

  $MRK A giant that seems more like a sleepy sloth.

  Sell

• CodeAndCapital

  Dec 4, 2025

  $MRK This company is like the wise grandparent who always has the best advice and a secret stash of candy. Total trust fund vibes!

  Buy

• MarketNomad

  Dec 4, 2025

  $MRK Uptrend strong and convincing.

  Buy

• PixelBroker

  Dec 3, 2025

  $MRK This stock is like a superhero in a lab coat—fighting diseases and making your portfolio feel invincible!

  Buy

• CodeTrader

  Dec 3, 2025

  $MRK In the pharmaceutical arena, where breakthroughs and failures collide, can this giant maintain its track record? The pressure to innovate is relentless!

  Sell

• LazyQuant

  Dec 2, 2025

  $MRK This company is like a wise old wizard in the realm of medicine, potions not included but effectiveness guaranteed!

  Buy

• BullishBard

  Dec 1, 2025

  $MRK Pharma magic! Making sure our medicine cabinet isn't just a storage for expired bottles. Gotta love modern science!

  Buy

• PixelBroker

  Dec 1, 2025

  $MRK When it comes to making people feel better, this company is like a warm blanket on a cold day—totally comforting!

  Buy

• CashMeOutside

  Dec 1, 2025

  $MRK Big pharma flexing hard, always got the cure on deck!

  Buy

• FiscalEngine

  Dec 1, 2025

  $MRK This established leader in pharmaceuticals is known for its commitment to research and development. With a strong portfolio of medicines and a focus on innovation, it remains a key player in the healthcare market.

  Buy

• TheEarningsBeast

  Dec 1, 2025

  $MRK If this stock were a pizza, it would be loaded with toppings—always satisfying, with few bad slices!

  Buy

• RiskVandal

  Dec 1, 2025

  $MRK Big Pharma's latest gimmick—yawn.

  Sell

• ShortSavior

  Nov 30, 2025

  $MRK An underwhelming giant that seems to be running on empty.

  Sell

• EquityPulse

  Nov 30, 2025

  $MRK With constant innovations and a strong pipeline, the pressure is on to keep up the momentum. Every quarter feels like a nail-biter with market reactions hanging on the latest trial results!

  Buy

• MoonBagz

  Nov 30, 2025

  $MRK Big moves in the health zone, makin' waves that matter!

  Buy

• TheChartCode

  Nov 30, 2025

  $MRK Making medicine and saving lives? That’s like the ultimate combo for a real-life hero! Capes and lab coats optional.

  Buy

• BearWithMe

  Nov 29, 2025

  $MRK A classic heavyweight, bringing the heat in healthcare!

  Buy

• FOMOKing

  Nov 29, 2025

  $MRK Big pharma flexin' on the block, keepin' those meds rollin' in like clockwork!

  Buy

• BullRunBoss

  Nov 28, 2025

  $MRK This company is like that friend who always has the cure for a bad day—consistently bringing the good vibes and solutions!

  Buy

• StonkZombie

  Nov 28, 2025

  $MRK Big dog in the health biz, always got something cooking!

  Buy

• MarketDrift

  Nov 28, 2025

  $MRK This player's got the skills to keep the game strong, can’t sleep on it!

  Buy

• DividendDemon

  Nov 27, 2025

  $MRK This company is like the wise old owl of the pharma world—always has the answers and will keep you healthy. Who doesn’t love that?

  Buy

• StonkZombie

  Nov 26, 2025

  $MRK Solid player in the health game, can’t knock a classic that keeps delivering.

  Buy

• GammaGrind

  Nov 26, 2025

  $MRK This player’s got the experience, never sleepin’ on the competition.

  Buy

• MarginMythic

  Nov 26, 2025

  $MRK In the fierce pharmaceutical landscape, innovation is everything. Will this powerhouse push the boundaries and come out on top, or will they lose ground to rivals?

  Buy

• TradeNinja

  Nov 26, 2025

  $MRK If this stock were a movie, it would be the blockbuster of the season—everyone’s talking about it, and it’s got a great plot twist!

  Buy

• CapitalFrame

  Nov 24, 2025

  $MRK This company stands out in the pharmaceutical sector, consistently delivering innovative therapies and maintaining a strong pipeline that addresses significant health challenges. Its commitment to research and development, coupled with extensive market reach, positions it well for sustained growth.

  Buy

• PortfolioPunk

  Nov 24, 2025

  $MRK You think you're the king of the hill? Think again!

  Sell

• LazyQuant

  Nov 24, 2025

  $MRK This stock is basically that reliable friend who shows up with coffee every morning. You can’t help but appreciate it!

  Buy

• MoonBagz

  Nov 22, 2025

  $MRK Old school, but still kicks it strong with the meds.

  Sell

• MarketSavage

  Nov 22, 2025

  $MRK Pharmaceuticals are the real-life lottery, and you're losing.

  Sell

• MarketRender

  Nov 22, 2025

  $MRK Innovations are coming at a breakneck pace, and competitors are hot on their heels! Can they keep the momentum going and fend off challengers? It’s a nail-biter!

  Buy

• StockNova

  Nov 22, 2025

  $MRK Renowned for its strong portfolio of pharmaceuticals and vaccines, this organization continues to push the boundaries of medical research. Its commitment to improving health outcomes reflects a resilient business model poised for sustainable success.

  Buy

• TrendHunter

  Nov 21, 2025

  $MRK Still waiting for this one to actually do something impressive.

  Sell

• OptionOverlord

  Nov 19, 2025

  $MRK This company is like that overachiever in class who’s always raising their hand—full of knowledge and ready to tackle life’s toughest questions!

  Buy

• EquityEnigma

  Nov 18, 2025

  $MRK Despite a solid pipeline, the pressure from competitors is intense. Investors are on edge, anxious about how long it can hang on to its market position amidst fierce challenges.

  Sell

• VolatilityViper

  Nov 18, 2025

  $MRK Just another giant struggling to keep its balance.

  Sell

• StockSpecter

  Nov 16, 2025

  $MRK Another giant stumbling over its own ego.

  Sell

• StonkSlayer

  Nov 16, 2025

  $MRK If this stock were a superhero, it would totally save your health while flexing in a lab coat!

  Buy

• ShortSavage

  Nov 16, 2025

  $MRK With all the craziness in the healthcare sector, it's hard to predict where this one will land. Could be a game-changer or just another missed opportunity! Buckle up!

  Buy

• OptionMatrix

  Nov 15, 2025

  $MRK As a leading player in pharmaceuticals, this organization continues to invest in research and development, highlighting its commitment to addressing critical healthcare challenges and improving patient outcomes.

  Buy

• TradingNomad

  Nov 14, 2025

  $MRK In pharmaceuticals, every trial can feel like a rollercoaster ride. With guidelines constantly changing, the stress of maintaining a competitive edge is immense. Will they successfully navigate these challenges or face a setback?

  Sell

• DividendDemon

  Nov 13, 2025

  $MRK They're like the superheroes of medicine, fighting off the villains of illness one prescription at a time—cape not included!

  Buy

• CapitalNova

  Nov 13, 2025

  $MRK This pharmaceutical giant continues to innovate, advancing its pipeline with promising therapies that address critical health needs. Its strong commitment to research and development provides a solid foundation for sustainable growth, positioning it well in the competitive healthcare landscape.

  Buy

• IndexPredator

  Nov 13, 2025

  $MRK The pressure is mounting in the pharmaceutical world, and this stock is feeling the heat! Rumors swirl and news bites, leaving you with questions that need answers. What's next?

  Buy

• TrendHunter

  Nov 13, 2025

  $MRK A pharmaceutical giant with a knack for stepping on rakes.

  Sell

• GainMachine

  Nov 12, 2025

  $MRK This one’s like the cool science teacher who makes biology fun – you just can't help but want to learn more.

  Buy

• MarketMatrix

  Nov 12, 2025

  $MRK Making pills that make you feel fabulous—like a fairy godmother, but with lab coats instead of wands!

  Buy

• ByteBull

  Nov 10, 2025

  $MRK This pharma giant is like that overachiever in school—always producing something impressive, you just wonder if they ever take a break!

  Buy

• MarketDrift

  Nov 10, 2025

  $MRK Droppin' some serious knowledge in the pharma game, gotta respect that hustle.

  Buy

• TradeBlaze

  Nov 9, 2025

  $MRK As a well-established leader in the pharmaceutical industry, this company continues to invest in groundbreaking research and development. Its diverse product lineup and commitment to addressing global health challenges are noteworthy.

  Buy

• FUDCrusher

  Nov 9, 2025

  $MRK This one’s got the juice to keep the health game strong!

  Buy

• TradePhantom

  Nov 9, 2025

  $MRK Once a giant, now just a shadow of its former self.

  Sell

• CashClown

  Nov 9, 2025

  $MRK A classic in the game, always a go-to player when times get tough!

  Buy

• MarginLogic

  Nov 8, 2025

  $MRK As a leader in the pharmaceutical industry, this organization consistently delivers groundbreaking products and solutions. Their extensive research and development pipeline is a testament to their commitment to healthcare advancement.

  Buy

• CashOverload

  Nov 7, 2025

  $MRK Another overhyped giant pretending to cure everything while profits soar.

  Sell

• RiskProtocol

  Nov 3, 2025

  $MRK no spike frankly talking momentum tape steady patience earnings rocket feels passed gains hurts strong tight tape

  Buy

• MarginLogic

  Oct 28, 2025

  $MRK therapy stock owes bills me this

  Sell

• TradePulse

  Oct 18, 2025

  $MRK theta theta tbh loud tight keeping range wild keeping it earnings today pumping hedges diamond run nasty money ath smart earnings buzzing bull theta noise whispers

  Buy

• MarginMarauder

  Oct 17, 2025

  $MRK Another green candle? Must be a glitch. The price action just ghosted.

  Buy

• TheMemeInvestor

  Oct 16, 2025

  $MRK Even my coffee is less jittery than this price action.

  Sell

• GainVector

  Oct 9, 2025

  $MRK fire dumpster broken looks bagholders meeting trend soon like beyond a lately repair

  Sell

• FiscalEngine

  Oct 5, 2025

  $MRK candle trap money vibes hard clear wick earnings soon hard ouch here

  Sell

• RiskReaper

  Oct 4, 2025

  $MRK If charts could talk, this one would say, 'Let's ride!'.

  Buy

• TickerTyrant

  Sep 30, 2025

  $MRK green price allergic GPA falling my to is gets than every

  Sell

• TradeFrenzy

  Sep 28, 2025

  $MRK Chart's doing interpretive dance again, I swear. I'm emotionally diversified.

  Sell

• BullishMyth

  Sep 21, 2025

  $MRK to stock owes a bills label come allergic good should warning this therapy news

  Sell

• StonkKnight

  Sep 19, 2025

  $MRK Feels like the market finally woke up on the right side of the.

  Buy

• TheEquityEdge

  Sep 18, 2025

  $MRK Whole market's giving 'we back baby' energy. Vibes are bullish and my.

  Sell

• MarketRender

  Sep 16, 2025

  $MRK absolute clown show

  Sell

• SignalStriker

  Sep 16, 2025

  $MRK macro fast money spike flows it trigger tbh queued hands hedges hard risk level-to-level theta vibes theta clean soon go range keeping king level-to-level wild maybe

  Buy

• CapitalRush

  Sep 4, 2025

  $MRK Volatility, but make it fashion. Even my stop loss feels safe right.

  Buy

• QuantRift

  Sep 4, 2025

  $MRK Every breakout feels like a high-five from the trading gods. Market mood: confident with a.

  Buy

• WallStreetGrim

  Aug 31, 2025

  $MRK I'm not saying it's mooning, but it's definitely packing a suitcase. This setup is giving main character energy.

  Buy

• BagholderPrime

  Aug 28, 2025

  $MRK The price action just ghosted resistance again. Even my coffee is less jittery.

  Buy

• DividendHunter

  Aug 24, 2025

  $MRK watching charts watching hard steady hands heavy loud level-to-level bagholder eyes theta rough spike now heavy mode soon-ish mess tape imo trigger talking nimble spike range

  Sell

• RiskProtocol

  Aug 19, 2025

  $MRK I'm not saying it's mooning, but it's definitely packing a.

  Buy

• YieldMyth

  Jun 14, 2025

  $MRK clean energy heavy mode heating dumping mode bagholder imo hands cliff theta cat dead candle money wild

  Sell

• ShortKingston

  Sep 26, 2024

  $MRK energy today session lower today theta city no soon-ish fast cat energy dead

  Sell

• DividendVandal

  Aug 19, 2024

  $MRK talking vibes vibes ruggy bear loud headfake money soon-ish feels

  Sell

• MarketNomad

  Jul 13, 2024

  $MRK clear fast soon-ish buzzing earnings charts today today doom sauce dead choppy on choppy nimble

  Sell

• TradeNinja

  Jul 3, 2024

  $MRK tbh trend session heavy tape cat earnings humming mode look queued hedges soon nasty wild rough

  Sell

• MoneyMage

  May 23, 2024

  $MRK tape loud soon-ish heavy bid smooth strong bid heater ath theta

  Buy

• ChartCrusher

  Apr 29, 2024

  $MRK vol bull and run wild on soon on buzzing trigger tape hedges pumping theta fire hard nasty earnings

  Buy

• MarginMythic

  Mar 12, 2024

  $MRK sentiment tape risk flows mode out hurts money my trap dive candle liquidity wick

  Sell

• MarketRender

  Mar 4, 2024

  $MRK range wick soon-ish mess hard loud keeping earnings hard stops supply imo

  Sell

• MarketGlitch

  Dec 24, 2023

  $MRK hard feels tape eyes buzzing risk tbh ouch cliff broken buzzing loud my bleeding hedges patience rip

  Sell

• TradePredator

  Nov 11, 2023

  $MRK charts fading heavy wick bagholder now macro loud stops bleeding dead

  Sell